Trial Profile
Safety, efficacy and pharmacokinetics of epratuzumab in patients with recurrent indolent non-Hodgkin's lymphoma
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 03 Nov 2015
Price :
$35
*
At a glance
- Drugs Epratuzumab (Primary)
- Indications Non-Hodgkin's lymphoma
- Focus Adverse reactions; Pharmacokinetics; Therapeutic Use
- 02 Nov 2015 New trial record